Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking (Q46702842)

24 December 2017

title

Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking (English)

1 reference

24 December 2017

0 references

1 reference

Tammy L Unruh

1

1 reference

24 December 2017

Haidong Li

2

1 reference

24 December 2017

Cathlin M Mutch

3

1 reference

24 December 2017

Neda Shariat

4

1 reference

24 December 2017

Lana Grigoriou

5

1 reference

24 December 2017

Ratna Sanyal

6

1 reference

24 December 2017

Christopher B Brown

7

1 reference

24 December 2017

Julie P Deans

8

1 reference

24 December 2017

publication date

1 October 2005

1 reference

24 December 2017

published in

Immunology

1 reference

24 December 2017

volume

116

1 reference

24 December 2017

issue

2

1 reference

24 December 2017

page(s)

223-232

1 reference

24 December 2017

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

From the bench to the bedside: ways to improve rituximab efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary struc

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

CD20-mediated apoptosis: signalling through lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Transient translocation of the B cell receptor and Src homology 2 domain-containing inositol phosphatase to lipid rafts: evidence toward a role in calcium regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

A cholesterol-dependent CD20 epitope detected by the FMC7 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

LAB: a new membrane-associated adaptor molecule in B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Non-T cell activation linker (NTAL): a transmembrane adaptor protein involved in immunoreceptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Store-operated cation entry mediated by CD20 in membrane rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

N-terminal protein acylation confers localization to cholesterol, sphingolipid-enriched membranes but not to lipid rafts/caveolae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1817827

The mechanisms of action of rituximab in the elimination of tumor cells

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1817827

Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1817827

Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1817827

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1817827

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

29 September 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2567.2005.02213.X

Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies

21 January 2018

1 reference

12 December 2020

Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism

1 reference

12 December 2020

Complement activation plays a key role in the side-effects of rituximab treatment

1 reference

12 December 2020

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines

1 reference

12 December 2020

Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2

1 reference

12 December 2020

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

12 December 2020

10.1111/J.1365-2567.2005.02213.X

Identifiers

DOI

1 reference

24 December 2017

PMC publication ID

1817827

0 references

1 reference

24 December 2017